TrialSite News Releases Groundbreaking Documentary Series “From The Front Lines” Spotlighting the Stories of Doctors, Clinicians, and Patients From Around the World Combating COVID-19, with the First Installation Focused on Peru’s Use of Ivermectin as an economical and widely available Therapeutic In this Fight For Life or Death
August 14, 2020
TrialSite News, the leading clinical-research-trial digital media platform, dedicated to independent and unbiased coverage and analysis of pharmaceutical trial developments from around the world, announces a groundbreaking new documentary series “From The Front Lines” chronicling the stories of doctors, clinicians and patients fighting the Covid-19 pandemic. TrialSite News is proud to announce the release of the first installation focusing on the use of Ivermectin to combat the Covid-19 pandemic in Peru. What are the factors behind Ivermectin, a common anti-parasite drug approved by the U.S. Food and Drug Administration (FDA), becoming a standard treatment for SARS-CoV-2, the virus behind COVID-19 in Peru? To view the documentary go here
As the pandemic spread fromWuhan, China to the rest of the world, by March 2020 Peru reported its first case of the pandemic. During this time, researchers at Monash University and Peter Doherty Institute in Australia demonstrated through cell culture experiments that Ivermectin kills SARS-CoV-2 at certain concentrations within 48 hours. As TrialSite has chronicled around the world, from Florida (U.S.), to Bangladesh, India, Egypt, Dominical Republic, Mexico and Brazil to the Andean nations of Peru and Bolivia, the use of Ivermectin spread like a wildfire as a treatment combating COVID-19. Peru became a particularly interesting story as Ivermectin was ultimately accepted by the national authorities as an off-label treatment acceptable against COVID-19.
But was this the right thing to do? Although at least three dozen Ivermectin-focused studies were initiated over the past few months, in Peru there weren’t any formal clinical trials generating sufficient evidence to back the claims that the drug was effective against the novel Coronavirus. TrialSite CEO, Publisher and Founder Daniel O’Connor commented, “As TrialSite has led the way chronicling various off-label treatments for COVID-19 around the world, including Ivermectin, the Peru story caught our attention. Our research uncovered that the drug was actually accepted by the Peruvian authorities as a common treatment for COVID-19. We were intrigued to better understand why and how this happened.”
TrialSite mobilized a team of professional filmmakers in Peru, whose mission was to expeditiously delve into the Peru Ivermectin story. Why was Ivermectin becoming a common treatment for COVID-19? Why were so many community-based doctors enthusiastic for the drug, while others vehemently remain opposed the use of the antiparasitic regimen as a treatment for COVID-19?
Visit TrialSite News to learn more about this 15-minute documentary. As the first installation in our groundbreaking original series “From The Front Lines”, TrialSite production shows us how Ivermectin became popular in Peru as COVID-19 treatment. What is the basis and justification for its use? Have formal clinical trials been undertaken there? And what have been the “real world” results in Peru during the pandemic?
About TrialSite News LLC
Based in Salt Lake City, Utah (The Silicon Slopes), TrialSite News® represents a new kind of clinical research news, information exchange, and global research collaboration initiative. We are dedicated 100% to transparent, open coverage of clinical research sites around the word. With an emphasis on the research trial site, this platform offers original news, intelligent aggregation, podcast interviews, research and analysis and a social network, TrialSite Connect®, dedicated solely for clinical research. Unlike other social networks where data is constantly censored and for sale, this is not the case with TrialSite Connect.
Jennifer Dredge- firstname.lastname@example.org